Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.31 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.31 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.30 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20174892 | 0.95 | ALK (0.33) | ALKKDM4EMEN1NPC1ALDH1A1 | |
| SCHEMBL20174906 | 0.95 | ALK (0.33) | ALKKDM4EMEN1NPC1ALDH1A1 | |
| SCHEMBL20199051 | 0.94 | PDK2 (0.32) | ALKMEN1KMT2APLA2G2APLA2G4A | |
| SCHEMBL20199067 | 0.94 | PDK2 (0.32) | ALKMEN1KMT2APLA2G2APLA2G4A | |
| SCHEMBL20174867 | 0.94 | PDK2 (0.32) | ALKMEN1KMT2APLA2G2APLA2G4A | |
| SCHEMBL20199021 | 0.94 | PDK2 (0.32) | ALKMEN1KMT2APLA2G2APLA2G4A | |
| SCHEMBL20174866 | 0.94 | PDK2 (0.32) | ALKMEN1KMT2APLA2G2APLA2G4A | |
| SCHEMBL20174865 | 0.94 | PDK2 (0.32) | ALKMEN1KMT2APLA2G2APLA2G4A | |
| SCHEMBL20174873 | 0.94 | PDK2 (0.32) | ALKMEN1KMT2APLA2G2APLA2G4A | |
| SCHEMBL20174896 | 0.92 | PDK2 (0.35) | ALKPLA2G2APLA2G4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10781366-B2 | Spiro compound and organic light-emitting device comprising same | LG CHEM, LTD. (KR) | 2020-09-22 | — | — | US | disclosed |
| US-20180148639-A1 | SPIRO COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME | LG CHEM, LTD. (KR) | 2018-05-31 | — | — | US | disclosed |
| US-20180148639-A1 | SPIRO COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME | LG CHEM, LTD. (KR) | 2018-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10781366-B2 | Spiro compound and organic light-emitting device comprising same | CRY1, NR2E3, ERG | ALK 2665/4885KDM4E 3633/4885MEN1 611/4885 |
| US-20180148639-A1 | SPIRO COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME | CRY1, NR2E3, ERG | ALK 2665/4885KDM4E 3633/4885MEN1 611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.